RVMD Q2 2025 Earnings
Reported Aug 6, 2025 at 4:05 PM ET · SEC Source
Q2 25 EPS
$-1.31
MISS 16.75%
Est. $-1.12
Q2 25 Revenue
N/A
Est. $27.5M
vs S&P Since Q2 25
+258.0%
BEATING MARKET
RVMD +271.9% vs S&P +14.0%
Market Reaction
Did RVMD Beat Earnings? Q2 2025 Results
Revolution Medicines delivered a disappointing second quarter, with its loss per share of $1.31 missing the consensus estimate of $1.12 by 16.75%, as the pre-revenue oncology company absorbed a steep acceleration in spending across its RAS-targeted p… Read more Revolution Medicines delivered a disappointing second quarter, with its loss per share of $1.31 missing the consensus estimate of $1.12 by 16.75%, as the pre-revenue oncology company absorbed a steep acceleration in spending across its RAS-targeted pipeline. The net loss widened to $247.79 million from $133.23 million a year earlier, driven primarily by R&D expenses surging to $224.13 million from $134.93 million as clinical trial costs and manufacturing investments for lead inhibitors daraxonrasib, elironrasib, and zoldonrasib scaled sharply. G&A expenses nearly doubled to $40.58 million as the company ramped commercial preparation activities. Despite the losses, Revolution Medicines maintained a robust cash position of $2.14 billion, bolstered by the first $250.00 million tranche from its $2.00 billion flexible funding agreement with Royalty Pharma, providing strategic runway for global development. FDA Breakthrough Therapy Designations for both daraxonrasib and elironrasib added regulatory momentum, and the company expects to complete enrollment of the pivotal RASolute 302 Phase 3 trial this year, with a data readout in 2026, while projecting a full-year 2025 net loss of $1.03 billion to $1.09 billion.
Key Takeaways
- • Increased clinical trial and manufacturing expenses for daraxonrasib, zoldonrasib and elironrasib
- • Headcount growth driving higher personnel-related expenses and stock-based compensation
- • Ramping commercial preparation activities
RVMD YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
“As we advance our innovative RAS(ON) inhibitors through late-stage development and prepare for potential commercialization, we are scaling the effort to meet the ever-growing opportunities afforded by our pipeline. With our maturing pipeline, organizational capabilities and recently bolstered financial wherewithal, we are on a path toward becoming a fully integrated, global oncology company with an industry-leading franchise of targeted therapies for patients with RAS-addicted cancers.”
— Mark A. Goldsmith, Q2 2025 Earnings Press Release
RVMD Earnings Trends
RVMD vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
RVMD EPS Trend
Earnings per share: estimate vs actual
RVMD Revenue Trend
Quarterly revenue: estimate vs actual
RVMD Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 MISS FY | $-1.58 | $-1.86 | -17.72% | — | — |
| FY Full Year | $-5.53 | $-5.95 | -7.53% | — | — |
| Q3 25 MISS | $-1.41 | $-1.61 | -14.25% | — | — |
| Q2 25 MISS | $-1.12 | $-1.31 | -16.75% | — | — |
| Q1 25 MISS | $-1.06 | $-1.13 | -7.02% | — | — |